Jared Richardson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jared Richardson has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amrutha Pattamatta
Center for NeuroGenetics, Colllege of Medicine, University of Florida, Gainesville, FL 32610, USA
2 shared publications - Eric Tzy-Shi Wang
Department of Molecular Genetics & Microbiology, Center for Neurogenetics, University of Florida, Gainesville, FL, USA
2 shared publications - John Andrew Berglund
RNA Institute, College of Arts and Sciences, University at Albany, SUNY, Albany, NY, USA
2 shared publications - Laura P. W. Ranum
Center for NeuroGenetics, College of Medicine, University of Florida
2 shared publications - Lauren A. Laboissonniere
Center for NeuroGenetics, Colllege of Medicine, University of Florida, Gainesville, FL 32610, USA
2 shared publications - Lien Nguyen
Center for NeuroGenetics, Department of Molecular Genetics and Microbiology, Genetics Institute, McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32610, USA
2 shared publications
Latest Publications
- Open Access
- 25 February 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 29 (24) , 3900-3918
Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice
C9orf72 ALS/FTD patients show remarkable clinical heterogeneity, but the complex biology of the repeat expansion mutation has limited our understanding of the disease. BAC transgenic mice were used to better understand the molecular mechanisms and repeat length effects of C9orf72 ALS/FTD. Genetic analyses of these mice demonstrate that the BAC transgene and not integration site effects cause ALS/FTD phenotypes. Transcriptomic changes in cell proliferation, inflammation and neuronal pathways are found late in disease and alternative splicing changes provide early molecular markers that worsen with disease progression. Isogenic sublines of mice with 800, 500 or 50 G4C2 repeats generated from the single-copy C9–500 line show longer repeats result in earlier onset, increased disease penetrance and increased levels of RNA foci and dipeptide RAN protein aggregates. These data demonstrate G4C2 repeat length is an important driver of disease and identify alternative splicing changes as early biomarkers of C9orf72 ALS/FTD.
- 25 February 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 29 (24) , 3900-3918
Open AccessRepeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice
C9orf72 ALS/FTD patients show remarkable clinical heterogeneity, but the complex biology of the repeat expansion mutation has limited our understanding of the disease. BAC transgenic mice were used to better understand the molecular mechanisms and repeat length effects of C9orf72 ALS/FTD. Genetic analyses of these mice demonstrate that the BAC transgene and not integration site effects cause ALS/FTD phenotypes. Transcriptomic changes in cell proliferation, inflammation and neuronal pathways are found late in disease and alternative splicing changes provide early molecular markers that worsen with disease progression. Isogenic sublines of mice with 800, 500 or 50 G4C2 repeats generated from the single-copy C9–500 line show longer repeats result in earlier onset, increased disease penetrance and increased levels of RNA foci and dipeptide RAN protein aggregates. These data demonstrate G4C2 repeat length is an important driver of disease and identify alternative splicing changes as early biomarkers of C9orf72 ALS/FTD.
- Open Access
Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice
C9orf72 ALS/FTD patients show remarkable clinical heterogeneity, but the complex biology of the repeat expansion mutation has limited our understanding of the disease. BAC transgenic mice were used to better understand the molecular mechanisms and repeat length effects of C9orf72 ALS/FTD. Genetic analyses of these mice demonstrate that the BAC transgene and not integration site effects cause ALS/FTD phenotypes. Transcriptomic changes in cell proliferation, inflammation and neuronal pathways are found late in disease and alternative splicing changes provide early molecular markers that worsen with disease progression. Isogenic sublines of mice with 800, 500 or 50 G 4 C 2 repeats generated from the single-copy C9-500 line show longer repeats result in earlier onset, increased disease penetrance, and increased levels of RNA foci and RAN aggregates. These data demonstrate G 4 C 2 repeat length is an important driver of disease and identify alternative splicing changes as early biomarkers of C9orf72 ALS/FTD.
Open AccessRepeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice
C9orf72 ALS/FTD patients show remarkable clinical heterogeneity, but the complex biology of the repeat expansion mutation has limited our understanding of the disease. BAC transgenic mice were used to better understand the molecular mechanisms and repeat length effects of C9orf72 ALS/FTD. Genetic analyses of these mice demonstrate that the BAC transgene and not integration site effects cause ALS/FTD phenotypes. Transcriptomic changes in cell proliferation, inflammation and neuronal pathways are found late in disease and alternative splicing changes provide early molecular markers that worsen with disease progression. Isogenic sublines of mice with 800, 500 or 50 G 4 C 2 repeats generated from the single-copy C9-500 line show longer repeats result in earlier onset, increased disease penetrance, and increased levels of RNA foci and RAN aggregates. These data demonstrate G 4 C 2 repeat length is an important driver of disease and identify alternative splicing changes as early biomarkers of C9orf72 ALS/FTD.